h2Abstract/h2 pstrongBackground: /strongMyocardial infarction (MI) is a cardiovascular disease that is the leading cause of death at all ages. Inflammation and oxidation processes constitute the basic pathophysiology of MI development. C-reactive protein (CRP) and transforming growth factor beta; (TGF-beta;) are markers that are often used to evaluate the level of inflammation, especially in MI./p pstrongObjective: /strongThis study aimed to evaluate the anti-inflammatory potential of thymoquinone (TQ), the major bioactive compound of emNigella sativa/em, by assessing its binding affinity through molecular docking, in which TQ exhibited more favorable binding energies compared to the native ligand./p pstrongMethods: /strongUsing the VegaZZ, PyMOL, and BIOVIA Discovery Studio tools, AutoDock Vina software was used for in silico research to test the active molecule TQ and produce visual profiles of native CRP and TGF-beta; ligands. Using the pkCSM method, pharmacokinetic predictions were carried out./p pstrongResults:/strong Thymoquinone (2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione) showed favorable binding affinity to both CRP and TGF-beta;, with docking scores of ndash;3.60 and ndash;4.15 kcal/mol, respectively, which are more favorable than those of the native ligands (ndash;2.39 and ndash;2.73 kcal/mol) and comparable to enalapril (ndash;4.84 and ndash;6.13 kcal/mol). The RMSD value for CRP was 1.421 Aring;, while the value for TGF-beta; was 0.253 Aring;, indicating excellent structural alignment and validating the docking approach./p pstrongConclusions: /strongThese in silico findings suggest that TQ warrants further investigation in vitro and in vivo as a potential modulator of inflammatory pathways in MI./p
Abduh et al. (Fri,) studied this question.